Cargando…

Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer

BACKGROUND: In non-inferiority trials of radiotherapy in patients with early stage breast cancer, it is inevitable that some patients will cross over from the experimental arm to the standard arm prior to initiation of any treatment due to complexities in treatment planning or subject preference. Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Parpia, Sameer, Julian, Jim A, Thabane, Lehana, Gu, Chushu, Whelan, Timothy J, Levine, Mark N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212183/
https://www.ncbi.nlm.nih.gov/pubmed/25344487
http://dx.doi.org/10.1136/bmjopen-2014-006531
_version_ 1782341669187747840
author Parpia, Sameer
Julian, Jim A
Thabane, Lehana
Gu, Chushu
Whelan, Timothy J
Levine, Mark N
author_facet Parpia, Sameer
Julian, Jim A
Thabane, Lehana
Gu, Chushu
Whelan, Timothy J
Levine, Mark N
author_sort Parpia, Sameer
collection PubMed
description BACKGROUND: In non-inferiority trials of radiotherapy in patients with early stage breast cancer, it is inevitable that some patients will cross over from the experimental arm to the standard arm prior to initiation of any treatment due to complexities in treatment planning or subject preference. Although the intention-to-treat (ITT) analysis is the preferred approach for superiority trials, its role in non-inferiority trials is still under debate. This has led to the use of alternative approaches such as the per-protocol (PP) analysis or the as-treated (AT) analysis, despite the inherent biases of such approaches. METHODS: Using simulations, we investigate the effect of 2%, 5% and 10% random and non-random crossovers prior to radiotherapy initiation on the ITT, PP, AT and the combination of ITT and PP analyses with respect to type I error in trials with time-to-event outcomes. We also evaluate bias and SE of the estimates from the ITT, PP and AT approaches. RESULTS: The AT approach had the best performance in terms of type I error, but was anticonservative as non-random crossover increased. The ITT and PP approaches were anticonservative under all percentages of random and non-random crossover. Similarly, lowest bias was seen with the AT approach; however, bias increased as the percentage of non-random crossover increased. The ITT and PP had poor performance in terms of bias as crossovers increased. CONCLUSIONS: If minimal crossovers were to occur, we have shown that the AT approach has the lowest type I error rates and smallest opportunity for bias. Results of trials with a high number of crossovers should be interpreted with caution, especially when crossover is non-random. Attempts to prevent crossovers should be maximised.
format Online
Article
Text
id pubmed-4212183
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42121832014-10-31 Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer Parpia, Sameer Julian, Jim A Thabane, Lehana Gu, Chushu Whelan, Timothy J Levine, Mark N BMJ Open Research Methods BACKGROUND: In non-inferiority trials of radiotherapy in patients with early stage breast cancer, it is inevitable that some patients will cross over from the experimental arm to the standard arm prior to initiation of any treatment due to complexities in treatment planning or subject preference. Although the intention-to-treat (ITT) analysis is the preferred approach for superiority trials, its role in non-inferiority trials is still under debate. This has led to the use of alternative approaches such as the per-protocol (PP) analysis or the as-treated (AT) analysis, despite the inherent biases of such approaches. METHODS: Using simulations, we investigate the effect of 2%, 5% and 10% random and non-random crossovers prior to radiotherapy initiation on the ITT, PP, AT and the combination of ITT and PP analyses with respect to type I error in trials with time-to-event outcomes. We also evaluate bias and SE of the estimates from the ITT, PP and AT approaches. RESULTS: The AT approach had the best performance in terms of type I error, but was anticonservative as non-random crossover increased. The ITT and PP approaches were anticonservative under all percentages of random and non-random crossover. Similarly, lowest bias was seen with the AT approach; however, bias increased as the percentage of non-random crossover increased. The ITT and PP had poor performance in terms of bias as crossovers increased. CONCLUSIONS: If minimal crossovers were to occur, we have shown that the AT approach has the lowest type I error rates and smallest opportunity for bias. Results of trials with a high number of crossovers should be interpreted with caution, especially when crossover is non-random. Attempts to prevent crossovers should be maximised. BMJ Publishing Group 2014-10-24 /pmc/articles/PMC4212183/ /pubmed/25344487 http://dx.doi.org/10.1136/bmjopen-2014-006531 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research Methods
Parpia, Sameer
Julian, Jim A
Thabane, Lehana
Gu, Chushu
Whelan, Timothy J
Levine, Mark N
Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title_full Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title_fullStr Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title_full_unstemmed Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title_short Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
title_sort treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
topic Research Methods
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212183/
https://www.ncbi.nlm.nih.gov/pubmed/25344487
http://dx.doi.org/10.1136/bmjopen-2014-006531
work_keys_str_mv AT parpiasameer treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer
AT julianjima treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer
AT thabanelehana treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer
AT guchushu treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer
AT whelantimothyj treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer
AT levinemarkn treatmentcrossoversintimetoeventnoninferiorityrandomisedtrialsofradiotherapyinpatientswithbreastcancer